facebook twitter twitter tiktok   donate



Suicide Crisis Helpline
0800 567 567

Department of Social Development Substance Abuse Helpline
0800 12 13 14
SMS 32312

Cipla Mental Health Helpline
0800 456 789
SMS 31393

NPOwer SA Helpline
0800 515 515
SMS 43010

Healthcare Workers Care Network Helpline
0800 21 21 21
SMS 43001

UFS #Fair Kitchens Chefs Helpline
0800 006 333


Dr Reddy’s Mental Health Helpline
0800 21 22 23

Adcock Ingram Depression & Anxiety Helpline
0800 70 80 90

ADHD Helpline
0800 55 44 33

Pharma Dynamics Police & Trauma Helpline
0800 20 50 26


011 234 4837


8AM – 5PM

Cipla Mental Health
076 882 2775

Maybelline BraveTogether
087 163 2030

Ke Moja Substance Abuse
087 163 2025

Have Hope Chat Line
087 163 2050


Contact Founder: Zane@sadag.org

Click Here

University and Higher Learning Helplines

student shaming

Student and Staff Emergency Contact Numbers - Click here


counsellor button

Request a Callback from a Counsellor
Click here



SADAG has over 160 free Support Groups. To find out more about joining or starting a Support Group click here.

Mental Health Calendar 2024

2023 Mental Health Calendar

To view our Mental Health Calendar
click here


questionnaire infographic

Do You want to check your Mental Health?

Click here for questionnaires

Deep Brain Stimulation Appears Effective For Depression, Bipolar Disorder

By Janice Wood Associate News Editor
Reviewed by John M. Grohol, Psy.D. on January 5, 2012

A new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression.

The study, led by researchers at Emory University in Atlanta, found that DBS works in patients with either unipolar major depressive disorder or bipolar II disorder.

“Depression is a serious and debilitating medical illness,” says Helen S. Mayberg, MD, a professor in the Departments of Psychiatry and Behavioral Sciences, Neurology and Radiology at Emory University School of Medicine, who led the study.

“When we found that the potential for effective and sustained antidepressant response with DBS for patients with otherwise treatment resistant major depressive disorder was high, the next step was to determine if patients with intractable bipolar depression could also be successfully treated.”

An earlier study by Mayberg done in Toronto in collaboration with scientists at Toronto Western Hospital, University Health Network and Emory, was the first to show such results for patients with treatment-resistant major depressive disorder. Mayberg conducted this new expanded trial at Emory to include patients with bipolar II disorder.

Bipolar spectrum disorder, sometimes referred to as manic-depression, is characterized by bouts of mania or hypomania alternating with episodes of depression. Although people with bipolar II disorder do not have full manic episodes, depressive episodes are frequent and intense, and there is a high risk of suicide, the researchers said.

A major challenge in treating bipolar depression is that many antidepressant medications may cause patients to “switch” into a hypomanic or manic episode, they add.

DBS uses high-frequency electrical stimulation targeted to a specific area of the brain. In the latest study, each of the 17 participants was implanted with two thin wire electrodes, one on each side of the brain. The other end of the wires were connected under the skin of the patient’s neck to a pulse generator implanted in the chest — similar to a pacemaker — that directed the electrical current.

Participants received single-blind stimulation for four weeks, not knowing if the DBS system was on or off. This was followed by active stimulation for 24 weeks. Patients were evaluated for up to two years following the onset of active stimulation.

A significant decrease in depression and an increase in function were associated with continuing stimulation, the researchers note. Remission and response rates were 18 percent and 41 percent after 24 weeks; 36 percent and 36 percent after one year; and 58 percent and 92 percent after two years of active stimulation.

Patients who achieved remission did not experience a spontaneous relapse, the researchers note.

Mayberg and her colleagues are continuing their research, studying demographic, clinical and imaging predictors of response and remission, and introducing psychotherapeutic rehabilitation. Why and how this treatment works is the primary focus of the ongoing research, Mayberg adds.

“Most of these patients have been in a depressed state for many years and are disabled and isolated,” says Dr. Paul E. Holtzheimer, lead psychiatrist on the study and now an associate professor and director of the Mood Disorders Service, Dartmouth Medical School.

“As their depression improves, they need a process to help them achieve full recovery that includes integration back into society. We hope to optimize the rate of improvement for these patients by using a model of care that provides psychotherapeutic rehabilitation built on evidence-based psychotherapy but tailored to the specific individual’s situation.”

Source: Emory University


Our Partners